Ting-Tsung Chang

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B

R. Gish, R. D. de Man, Y. Chao, 2009, Journal of viral hepatitis.

The impact of smoking on incident type 2 diabetes in a cohort with hepatitis B but not hepatitis C infection

Chong-Shan Wang, Ting-Tsung Chang, Pesus Chou, 2017, Journal of viral hepatitis.

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

P. Thuluvath, D. Mutimer, C. Hézode, 2018 .

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B *

R. D. de Man, F. Poordad, Joanna Y Yang, 2010, Journal of viral hepatitis.

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients

W. Su, W. Chuang, Ed Luo, 2024, Clinical and molecular hepatology.